title: [Montelukast in the treatment of mild to moderate persistent asthma].
abstract: BACKGROUND
  Anti-inflammatory preventive treatment is recommended in cases of persistent asthma. Besides inhaled corticosteroids (ICS), which represent the mainstay of treatment, other therapeutic options are available, of which only antileukotrienes are approved for all age groups.
  
  
  BACKGROUND
  Given as a substitute of low-dose ICS, montelukast prevents exacerbations as efficiently and for a longer period than long-acting β2-agonists. Montelukast is as efficient as doubling the dose of ICS on asthma symptoms in cases of inadequate control with low-dose ICS. Combined with ICS, it can lead to better control of asthma and potentially to ICS sparing.
  
  
  CONCLUSIONS
  Given the efficacy, tolerance and long-term treatment compliance of montelukast in mild persistent asthma in adults and children, montelukast, given as a substitute or combined with ICS, could contribute to enhanced control of asthma, especially in children.
authors: Service de pneumologie, centre hospitalier Lyon-Sud, HCL, pavillon médical, Pierre-Bénite cedex, France.
authors: V
authors: V
authors: Bellecoste
authors: G
authors: G
authors: Devouassoux
authors: Y
authors: Y
authors: Pacheco
mesh_terms: D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D056151:Airway Remodeling; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D003521:Cyclopropanes; D016207:Cytokines / Q000378:metabolism; D004359:Drug Therapy, Combination; D005602:France / Q000453:epidemiology; D006801:Humans; D007249:Inflammation; D020024:Leukotriene Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D015289:Leukotrienes / Q000502:physiology; D008954:Models, Biological; D017410:Practice Guidelines as Topic; D015995:Prevalence; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018077:Receptors, Leukotriene / Q000187:drug effects / Q000502:physiology; D013440:Sulfides
chemical_list: D000085:Acetates; D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D003521:Cyclopropanes; D016207:Cytokines; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D011804:Quinolines; D018077:Receptors, Leukotriene; D013440:Sulfides; C083169:leukotriene D4 receptor; C093875:montelukast